Final Bidding Day for Mukka Proteins IPO: Oversubscribed 83.10 Times, Driven by NIIs and Retail Investors Get the Latest GMP.
2 min read 2024-03-04, 04:40PM IST
Summary⇒Encouraging investors to review any recent allotments and focusing on opportunities for the week ahead. ⇒Mentioning the availability of four new videos detailing upcoming IPOs and strategies for investors. ⇒Highlighting Mukka Proteins Limited as the IPO of focus, set to debut on the 29th, and briefly mentioning last week’s offerings. ⇒Noting the significant interest in Mukka Proteins, but advising caution due to the nature of the business. ⇒Offering reassurance to those who missed out on previous allotments or chose not to apply, highlighting potential benefits from this IPO. ⇒Emphasizing the importance of monitoring subscription trends and recognizing entry points. ⇒Explaining the competitive allocation process and the opportunity it presents for smaller investors. ⇒Summarizing the company’s impressive revenue growth, projected profit, debt levels, and market cap. ⇒Highlighting Mukka Proteins’ operations in multiple countries, indicating diverse revenue streams and potential for growth. ⇒Noting the company’s market cap and its attractiveness as an investment prospect. ⇒Pointing out promising returns, supported by return on equity and debt-to-equity ratio, while advising investors to conduct thorough due diligence. |
As we embark on a new week, let’s take a moment to reflect on any recent allotments. If you haven’t received one yet, don’t worry! Let’s focus on the opportunities this week brings. I’ve prepared four new videos for you, detailing the upcoming IPOs and strategies to navigate them. Whether you’re a seasoned investor or just starting out, there’s valuable insight for everyone.
ALSO READ| Blue Jet Healthcare IPO.
Let’s dive into the IPOs lined up for this week. Today, we’re discussing Mukka Proteins Limited, set to debut on the 29th. But before we delve into the specifics, let’s recap last week’s offerings, Exicom and Platinum, which received a fantastic response.
Now, onto Mukka Proteins. This IPO is generating significant interest, with over a lakh applications already pouring in. It’s crucial to approach this opportunity with caution. While the company operates in the lucrative non-veg category, not everyone may find it suitable for their portfolio.
For those who missed out on previous allotments or chose not to apply, fear not. There’s still potential to benefit from this IPO. Keep an eye on subscription trends, as fluctuations may present entry points. Additionally, be mindful of the allocation process. With only 5,233 allotments available, competition is fierce. However, smaller investors stand a chance, with over 54% reserved for them.
Let’s break down the numbers further. In the retail category, subscription is nearly 10 times oversubscribed, while overall demand exceeds seven times. Despite the high demand, retail investors can secure 535 shares for just ₹1, resulting in a modest investment of ₹14,980. Larger investors stand to gain even more, with thousands of shares up for grabs.
Now, let’s analyze the company’s financials. Mukka Proteins has demonstrated impressive revenue growth, with a projected profit of ₹50 crores. This year’s revenue is expected to surpass ₹1,500 crores, showcasing robust performance. While debt levels have increased, the company maintains strong fundamentals, supported by reserves and a market cap of ₹840 crores.
Looking beyond financials, Mukka Proteins operates not only in India but also in ten other countries, offering diverse revenue streams. This global presence underscores its potential for further growth.
In terms of valuation, the company’s market cap of ₹840 crores presents ample room for expansion, making it an attractive prospect for investors. With a return on equity of 36% and a decent debt-to-equity ratio, Mukka Proteins offers promising returns.
In conclusion, Mukka Proteins Limited presents a compelling investment opportunity. However, investors should conduct thorough due diligence and assess their risk tolerance before participating. Keep an eye on subscription trends and consider your allocation strategy carefully. With the right approach, this IPO could prove to be a lucrative addition to your portfolio.
Don’t forget to watch the detailed video for comprehensive insights into Mukka Proteins and other upcoming IPOs. Stay informed, stay vigilant, and may your investments yield great returns.
